ðə kˌɔːɹpɚɹˈeɪʃən wʌz ˈɔːlsoʊ kɹˈɪɾɪsˌaɪzd fɔːɹ sˌʌm dɪzˈaɪn ˈɛlɪmənts ʌv ɪts klˈɪnɪkəl tɹˈaɪəlz ɹᵻlˈeɪɾᵻd tə ðə nˈiːd tə pɚfˈɔːɹm kɹˈɪɾɪkəl kˈɛɹ ænd ɹᵻsˌʌsɪtˈeɪʃən wˌaɪl pˈeɪʃənts wɜːɹ ɪn ɡɹˈeɪv klˈɪnɪkəl kəndˈɪʃənz dˈuː tə ðə mˈɛkənˌɪzəmz ʌv ˈɪndʒɚɹi ɪŋkˈɜːd ænd ðə kˈɑːnsɪkwənt ɪnɐbˈɪləɾi ʌv pˈeɪʃənts tə pɹəvˈaɪd ɪnfˈɔːɹmd kənsˈɛnt fɔːɹ tɹˈiːtmənt.
The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.